Navigation Links
Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
Date:6/8/2008

n ALS, cancer, HIV/AIDS, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN(TM)) for gene modification. Sangamo has established strategic partnerships with companies outside of the human therapeutic space including Dow AgroSciences, Sigma-Aldrich Corporation and several companies applying its ZFP Technology to enhance the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at http://www.sangamo.com.

This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to the clinical trials of SB-509, research and development of novel ZFP TFs and ZFNs and therapeutic applications of Sangamo's ZFP technology platform. Actual results may differ materially from these forward-looking statements due to a number of factors, including uncertainties relating to the initiation and completion of stages of the SB-509 clinical trials, whether the SB-509 clinical trials will validate and support tolerability and efficacy of SB-509, technological challenges, Sangamo's ability to develop commercially viable products and technological developments by our competitors. See Sangamo's SEC filings, and in particular, the risk factors described in the it's Annual Report on Form 10-K and its most recent Quarterly Report on Form 10-Q. Sangamo BioSciences, Inc. assumes no obligation to update the forward-looking information contained in this press release.


'/>"/>
SOURCE Sangamo BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
2. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
3. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
4. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
5. Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
6. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
7. Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System
8. Magellan Biosciences Companies to Feature Automated Products and New Tests for MRSA at the American Society for Microbiology Meeting, Booth 743
9. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
10. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
11. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... March 26, 2015  Oxis Biotech, Inc. ... International, Inc. [OTC: OXIS] and [Euronext Paris: ... exclusive option agreement with the University of ... by Dr. Xiang-Qun Xie , Associate ... Sciences, School of Pharmacy.  These patents/intellectual properties ...
(Date:3/26/2015)... BUENA, N.J. , March 26, 2015 ... New Jersey based specialty generic pharmaceutical company, ... drug application (ANDA) to the U.S. Food and Drug ... number of ANDA submissions now pending at the FDA ... and CEO of the Company, commented, "On March 2, ...
(Date:3/26/2015)... , March 26, 2015  CNBC profiled MJ Freeway ... part of a series "How I Did It," which features ... the High Road" released yesterday, illustrates how two tech ... leading IT providers to the marijuana industry. ... describes how Co-Founders Amy Poinsett and Jessica Billingsley ...
Breaking Medicine Technology:Oxis Biotech Executes Option Agreement to Certain Patents/Intellectual Properties Owned by the University of Pittsburgh 2Oxis Biotech Executes Option Agreement to Certain Patents/Intellectual Properties Owned by the University of Pittsburgh 3IGI Laboratories, Inc. Announces First ANDA Submission Of 2015 2MJ Freeway, Industry-Leading Software Solution for Cannabis Businesses, Featured in CNBC Special "How I Did It" 2
(Date:3/26/2015)... York (PRWEB) March 26, 2015 ... move forward nationwide, with the issuance of new ... Pennsylvania and Louisiana. According to an Order dated ... litigation established for Xarelto injury claims in the ... now allow plaintiffs to file cases directly in ...
(Date:3/26/2015)... March 26, 2015 “The SWEET Act is ... healthy options more available and help parents who are working ... is a reasonable approach to support public health, and we ... issue for the health of all families,” said Dr. Jane ... Health on the introduction of the Sugar-Sweetened Beverage Tax (SWEET) ...
(Date:3/26/2015)... CA (PRWEB) March 26, 2015 Dr. ... are proud to announce expanded offerings for Bay Area ... Francisco Dental Implant Center has long been a top-rated ... expanded its offerings to meet the strong demand by ... our reputation as a top-rated dental implant facility in ...
(Date:3/26/2015)... Altamonte Springs, FL (PRWEB) March 26, 2015 ... one of the nation’s leading innovative specialty pharmacies, ... newly created position of Vice President of Pharmaceutical ... for fostering beneficial connections with our pharmaceuticals partners ... pharmaceutical relationships in support of BioPlus’ expansion. ...
(Date:3/26/2015)... London, UK (PRWEB) March 26, 2015 In ... 40 billion as of 2013 and is set to decrease ... billion by 2020; the growth is expected up to 2017 ... growth is expected to be owing to the surging penetration ... Tekturna HCT, Twynsta, Micardis Plus, Valturna, Benicar HCT, and Tekamlo), ...
Breaking Medicine News(10 mins):Health News:Xarelto Lawsuits Move Forward Nationwide, With Issuance of New Court Docs in State, Federal Litigations 2Health News:Xarelto Lawsuits Move Forward Nationwide, With Issuance of New Court Docs in State, Federal Litigations 3Health News:National Alliance for Hispanic Health Statement on Introduction of SWEET Act in 114th Congress 2Health News:Bay Area Dental Implant Specialist, Dr. Alex Rabinovich Announces Regional Educational Strategy 2Health News:Bay Area Dental Implant Specialist, Dr. Alex Rabinovich Announces Regional Educational Strategy 3Health News:BioPlus Specialty Pharmacy Expands Executive Team with New Position, Naming Sharon Ferrer as Vice President of Pharmaceutical Relations 2Health News:Top 8 Developed Anti-Hypertensive Therapeutics Markets Discussed in New GBI Research Report Published at MarketPublishers.com 2Health News:Top 8 Developed Anti-Hypertensive Therapeutics Markets Discussed in New GBI Research Report Published at MarketPublishers.com 3
... 81-year-old San Francisco woman with dementia, little money and an equally aged ... A 72-year-old Riverside woman with Alzheimer,s who cannot be left safely on ... care for her. A 78-year-old Los Angeles ... take care of him if day care services are cut. ...
... Angeles, London, New Delhi, Singapore and Washington DC (October ... with diabetes to modify their behavior, adjust their medicine ... to a recent study, published by SAGE in ... testing," a self-monitored testing both before and after specific ...
... remains a mystery, , THURSDAY, Oct. 1 (HealthDay News) -- ... still in their mother,s womb were about 20 percent more ... study has found. , The flu outbreak in 1918 killed ... the United States. That flu, like the current H1N1 swine ...
... ... to maximize cell culture media performance and will be on display at BioProcess International ... in Raleigh, North Carolina. , ... Fort Collins, CO (PRWEB) October 1, 2009 -- As conference exhibitor and ...
... The 2nd ... in New York, NY. This three-day conference will explore address all aspects of signal detection ... ... The 2nd DIA Conference on Signal Detection and Data Mining will be held ...
... Support for Addressing Crisis of Chronic Disease , ... are voicing their support for health reform that prioritizes ... to Health Reform" ( www.sayyestohealthreform.com ) - an ... (PFCD) directed at Congressional leaders in Washington. , The campaign ...
Cached Medicine News:Health News:Half-million low-income elderly affected by sweeping cuts to state safety net 2Health News:Half-million low-income elderly affected by sweeping cuts to state safety net 3Health News:Pre-Birth Exposure to 1918 Flu Raised Heart Risks, Study Finds 2Health News:Pre-Birth Exposure to 1918 Flu Raised Heart Risks, Study Finds 3Health News:InVitria's Better Ingredients for Better Media to be Showcased at BPI '09 2Health News:International Experts to Review State-of-the-Art Thinking on Signal Detection and Data Mining 2Health News:International Experts to Review State-of-the-Art Thinking on Signal Detection and Data Mining 3Health News:Maryland Residents Participate in Launch of National Video Campaign: 'Say 'Yes' to Health Reform' 2Health News:Maryland Residents Participate in Launch of National Video Campaign: 'Say 'Yes' to Health Reform' 3
This is an Immunological assay intended for the quantitative in vitro determination of haemoglobin A1c (HbA1c) in whole blood....
For the quantitative in vitro determination of Sodium in serum and plasma....
Immunoturbidimetric assay for the quantitative in vitro determination of Lipoprotein (a) in human serum or plasma...
Immunoturbidimetric assay for the quantitative in vitro determination of Lipoprotein (a) in human serum or plasma...
Medicine Products: